Furthermore, previous studies showed that ANXA3 can promote CD133+ CSCs but there is no such meticulous distinction observed in the CSCs from lung or liver carcinoma, usually defined as the CD133+ population25, so the divergence between our current study and others’ studies in functional assays is understandable. This evidence concerns the gene PROM1 and hepatocellular carcinoma.